Celularity Inc. Files Form 8-K: Key Updates for Shareholders
Overview
Celularity Inc. (NASDAQ: CELU) has filed a Form 8-K with the U.S. Securities and Exchange Commission, reporting key information relevant to investors and shareholders. The filing, dated June 9, 2026, covers current events and disclosures pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Points from the Filing
- Filing Type: Form 8-K – Current Report
- Date of Report: June 9, 2026
- Trading Symbols:
- Class A Common Stock: CELU
- Warrants: CELUW
- Exchange: Nasdaq Stock Market LLC
- Share Classes Reported:
- Class A Common Stock, \$0.0001 par value per share
- Warrants, each exercisable for one-tenth of one share of Class A Common Stock at an exercise price of \$11.50 per share
- Emerging Growth Company: Celularity Inc. is identified as an emerging growth company under SEC rules.
- Extended Transition Period: The company has not elected to use the extended transition period for complying with any new or revised financial accounting standards.
- Amendment Flag: The Form 8-K is not an amendment to a previous filing.
Important Shareholder Information
-
Potential Listing Risk:
The filing specifically states: “There can be no assurance that the Company will be successful in maintaining its listing of its common stock on the Nasdaq Capital Market.” This is a critical disclosure for shareholders, as the risk of delisting could significantly impact share value and liquidity. Investors should monitor the company’s ongoing compliance with Nasdaq’s listing requirements.
-
No Price-Sensitive Corporate Actions Reported:
The Form 8-K does not indicate any new written communications under Rule 425, soliciting material under Rule 14a-12, or pre-commencement tender or issuer tender offers under Rules 14d-2(b) or 13e-4(c). This means there are no current corporate actions related to mergers, acquisitions, or tender offers that might move the share price.
-
Security Details:
- Class A Common Stock (CELU) and Warrants (CELUW) remain listed on Nasdaq.
- Warrants are exercisable for one-tenth of one share of Class A Common Stock at \$11.50 per share, which may be relevant for warrant holders assessing dilution risk or investment opportunities.
-
Emerging Growth Company Status:
Celularity’s status as an emerging growth company may allow it to benefit from reduced regulatory requirements, potentially affecting future financial disclosures and reporting timelines.
Potential Share Price Impact
The most price-sensitive disclosure is the risk statement regarding Nasdaq listing compliance. If Celularity fails to maintain its listing, shareholders could face reduced liquidity and potential forced selling, which would likely have a negative impact on the share price. Investors should also consider the implications of warrant exercise terms, especially as they relate to dilution and capital structure.
Conclusion
While there are no immediate corporate actions or amendments reported in this Form 8-K, the explicit mention of listing risk is a material concern for shareholders. Investors should continue to monitor Celularity Inc.’s compliance with Nasdaq requirements and any future filings that may provide updates on this situation.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. The information provided is based on the Celularity Inc. Form 8-K filed on June 9, 2026, and may be subject to change as new disclosures are made.
